* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download ZJ presentation on antibiotic resistance
Survey
Document related concepts
Transmission (medicine) wikipedia , lookup
Traveler's diarrhea wikipedia , lookup
Antimicrobial peptides wikipedia , lookup
Gastroenteritis wikipedia , lookup
Hygiene hypothesis wikipedia , lookup
Childhood immunizations in the United States wikipedia , lookup
Staphylococcus aureus wikipedia , lookup
Infection control wikipedia , lookup
Urinary tract infection wikipedia , lookup
Neonatal infection wikipedia , lookup
Anaerobic infection wikipedia , lookup
Transcript
ECDC-EMEA Joint Technical Report Part I: Trends and burden of antimicrobial resistance in the European Union Zsuzsanna Jakab, Director European Centre for Disease Prevention and Control Jönköping, 6 July 2009 General background Antimicrobial resistance (AMR) is still a growing European and global health problem. (Council Conclusions on Antimicrobial Resistance (AMR), Luxembourg, 10 June 2008) Prevention and control of AMR can be achieved by: – Prudent use of existing of antimicrobial agents – Good hygiene practices (infection control) – Novel antimicrobial agents active on resistant bacteria Need to ascertain the perceived gap between: – infections due to resistant bacteria – development of novel agents aimed at treating such infections Background for ECDC-EMEA Joint Report ECDC-EMEA Joint Working Group (established February 2008) Mandate – To produce a report on “the gap between the increasing prevalence of multidrug-resistant bacteria and antibacterial drug development aimed at treating such infections” Composition – ECDC appointed experts – EMEA appointed experts – ECDC and EMEA staff – Co-opted experts, e.g. from ReAct – Observers: European Commission, ESCMID Methods (1): Selected resistant bacteria of public health importance Based on the most frequent bacteria responsible for bloodstream infections Certain resistances were used as indicators for multidrug resistance (resistance to multiple antibiotics) 6 most frequent resistant bacteria: Gram-positive-bacteria Methicillin-resistant Staphylococcus aureus (MRSA) Vancomycin-resistant Enterococcus faecium (VRE) Penicillin-resistant Streptococcus pneumoniae Gram-negative bacteria Third-generation cephalosporin-resistant Escherichia coli Third-generation cephalosporin-resistant Klebsiella pneumoniae Carbapenem-resistant Pseudomonas aeruginosa Source: EARSS & Biedenbach DJ et al., 2004. Methods (2): Trends and burden of human infections due to resistant bacteria Trends – Data on resistant bacteria from bloodstream infections (European Antimicrobial Resistance Surveillance System EARSS) – 2002-2007 Human burden – Extrapolations for 4 main types of infection (bloodstream, respiratory tract, skin and soft tissue, urinary tract) – Extrapolations of burden parameters from published literature (e.g.: attributable mortality, extra length of stay in hospital) Economic burden – Extra in-hospital costs – Productivity losses due to absence from work because of illness and premature death of infected patients Percentage of resistant isolates in bacteria from bloodstream infections, EU countries, Iceland and Norway, 2007 No. of countries Country with a significant increase (2005-2007) Country with a significant decrease (2005-2007) Methicillin-resistant S. aureus - MRSA (%) 3rd-gen. ceph.-resistant Escherichia coli (%) Source: EARSS & ECDC, 2009 3rd-gen. ceph.-resistant Klebsiella pneumoniae (%) Population-weighted, average %resistant isolates among bacteria from bloodstream infections, EU, Iceland and Norway, 2002-2007 10 2011 2010 2009 2008 2007 2006 0 2005 2011 2010 2009 2008 2007 2006 2005 2004 2003 0 20 2004 10 30 2003 20 40 2002 30 Gram-negative bacteria Population-weighted average proportion of resistant isolates (%) 40 2002 Population-weighted average proportion of resistant isolates (%) Gram-positive bacteria Methicillin-resistant S. aureus (MRSA) Third-gen. cephalosporin-resistant E. coli Vancomycin-resistant E. faecium Third-gen. ceph.-resistant K. pneumoniae** Penicillin-resistant S. pneumoniae* Carbapenem-resistant P. aeruginosa** *Excluding Greece, which did not report data. Source: EARSS & ECDC, 2009 **Excluding Belgium and Slovakia, which did not report data. Burden of multidrug-resistant (MDR) bacteria in the EU, Iceland and Norway Human burden Infections (6 most frequent MDR bacteria, 4 main types of infection) approx. Attributable deaths 400,000 / year approx. 25,000 Extra hospital days approx. 2.5 million Extra in-hospital costs approx. € 1 billion Productivity losses approx. € 600 million / year / year Economic burden / year / year Limitation: these are underestimates. Source: ECDC, 2009 Conclusions Resistance to antibiotics is high in bacteria that cause serious infections in humans. Resistance is increasing among certain bacteria (i.e., Gram-negative bacteria). Infections caused by multidrug-resistant bacteria are associated with excess morbidity and mortality. These infections are associated with substantial extra costs.